Legal Status and Regulatory Considerations

How the two peptides differ legally

BPC-157 and TB-500 are usually sold and stacked as a pair, but regulators don't always treat them the same way. For a tested athlete, the difference is which section of the anti-doping list applies. For everyone else, the questions are whether anyone can lawfully sell them for human use and what happens to a package at the border. As of October 2026, neither peptide is an approved medicine in the US, Canada or Australia, and that fact drives most of what follows.

This page covers the legal side only. The research behind each compound is in the main BPC-157 vs TB-500 comparison.

Sports Organizations

WADA Status

WADA's 2026 Prohibited List, in force since January 1, 2026, names BPC-157 in S0. That class covers any substance not addressed elsewhere on the list that has "no current approval by any governmental regulatory health authority for human therapeutic use." TB-500 sits in a different class: S2.3 lists "Thymosin-β4 and its derivatives e.g. TB-500" among growth factors. Older tables that describe BPC-157 as "not explicitly listed" or file TB-500 under peptide hormones in general are out of date.

The two classes differ in one technical way. Everything in S0 is a "Specified Substance," while everything in S2 is non-Specified. The list explains that this label is used when sanctions are set under Article 10 of the World Anti-Doping Code, and that Specified substances shouldn't be seen as "less important or less dangerous" than others. Either way, both peptides are banned in and out of competition.

The 2027 List was published in September 2026 and takes effect on January 1, 2027. According to USADA's athlete advisory, it now names "peptides" in general as an example of an S0 non-approved substance. BPC-157 and TB-500 stay prohibited.

WADA's wording on TB-500 also settles a question users raise often. Vials sold as TB-500 are supposed to hold a seven-amino-acid fragment of thymosin beta-4, and some buyers aren't sure whether theirs contain the fragment or the full protein. The S2.3 entry covers thymosin beta-4 "and its derivatives," so both are prohibited. The biology behind that distinction is covered in how BPC-157 and TB-500 work at the cellular level.

Drug Testing Considerations

Anti-doping labs have published test methods for both peptides. In 2012, the doping control lab at Ghent University identified the acetylated 17-23 fragment of thymosin beta-4 (Ac-LKKTETQ) in a TB-500 product and proposed a way to detect it in plasma and urine. In 2017, a Salt Lake City sports testing lab found BPC-157 in confiscated vials and validated a urine test with a detection limit of 0.1 ng/mL. A 2026 Ghent paper described a single workflow that screens dried blood spots, serum and plasma for 54 prohibited compounds. Both peptides are among them.

We found no published human data on how long either peptide stays detectable after use, so the detection windows quoted on forums aren't backed by any study we could locate. USADA reminds athletes that they are strictly liable for whatever is in their system.

Professional Sports

Professional leagues and the NCAA set their own drug policies, as do tested bodybuilding federations. We didn't review them for this update, so the WADA position above is the only one this page confirms. USADA points athletes to Global DRO and its Drug Reference Line for questions about specific substances, and notes that Global DRO doesn't list every prohibited peptide by name.

Regulatory Classification

United States

As of October 2026, neither BPC-157 nor TB-500 is an FDA-approved drug. Their status for pharmacy compounding changed twice in 2026.

• April 2026. On April 15, FDA announced it would remove 12 peptides from Category 2 of its interim 503A bulk substances list, the category for substances that raise significant safety concerns, because their nominations had been withdrawn. BPC-157 and "Thymosin Beta-4, Fragment (LKKTETQ) (TB-500)" were both on the list, and the removal took effect in late April. Law firm Frier Levitt noted that removal doesn't put a substance in Category 1 or on the 503A bulks list, so pharmacies gained no new permission to compound either one.
• July 2026. At its July 23-24 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8-6-1 to recommend adding BPC-157 and TB-500 to the 503A bulks list, against the cautious position of FDA staff, according to LumaLex Law and CBS News. The vote is advice. FDA would still have to publish a proposed rule, take public comment and issue a final rule.

As of October 2026, we found no proposed rule for either peptide in the Federal Register. Until FDA acts, a US compounding pharmacy has no clear legal basis for making either one.

Most BPC-157 and TB-500 in the US is sold online as "research use only." FDA's 2026 warning letters show how the agency reads that label. Its August 24, 2026 letter to Peak Performance Peptides said that "despite statements on your product labeling marketing your products for 'research use only' and 'not for human consumption,'" evidence from the company's website showed the products were intended as drugs for human use. The letter also cited the company's sale of bacteriostatic water for reconstituting its products. That letter concerned other peptides, such as retatrutide and SS-31, but its reasoning doesn't depend on which compound is in the vial.

Criminal enforcement has reached this market as well. In July 2026, a federal judge sentenced the owner of Paradigm Peptides to 70 months in prison after he pleaded guilty to selling unapproved drugs and illegally importing them. CBS News reported that BPC-157 was among the unapproved drugs he was charged with selling, and in his plea he admitted knowing the products were marketed and sold for human consumption.

The 2026 federal actions described here targeted sellers, not buyers. That's a pattern, not a legal protection. Imports carry their own risk: US Customs and Border Protection reported seizing about 5,000 mis-declared peptide shipments at the Port of Cincinnati between December 2025 and March 2026. Most held GLP-1 ingredients, and the agency said imported drugs must meet FDA standards. State laws weren't reviewed for this update.

Canada

Health Canada's April 9, 2026 public advisory (RA-81874) lists BPC-157 and TB-500 among unauthorized injectable peptides it has seized, and says it's working with the Canada Border Services Agency to stop shipments. The advisory says peptides are generally regulated as prescription drugs in Canada and that unauthorized drug products are illegal. It adds that a research-use-only label "does not make these products legal or exempt from regulatory requirements."

Australia

The TGA's April 13, 2026 safety alert names BPC-157 and TB-500 among its examples of unapproved peptide products. It states that a "research use only" disclaimer doesn't make supply lawful, change a product's regulatory status or permit importation. People importing under the Personal Importation Scheme must meet the scheme's conditions. Those include a prescription or medical authorisation where one is required, and the TGA says products with unclear or code-only labels won't be considered for release. State and territory laws may add their own controls, including on possession. We couldn't confirm how the Poisons Standard schedules either peptide for this update.

United Kingdom

The UK sources reviewed for this update don't name BPC-157 or TB-500. MHRA enforcement in 2026 has centered on unlicensed weight-loss medicines. In May 2026 its Criminal Enforcement Unit arrested two people, on suspicion of offences under the Human Medicines Regulations 2012, at a site it believes was making and distributing retatrutide and tirzepatide along with other peptide products. Readers in the UK will need to check MHRA guidance directly for these two peptides.

European Union

Rules in individual EU member states weren't researched for this update, and we haven't confirmed how any of them classify BPC-157 or TB-500.

Purchasing Considerations

Buying from an unregulated market means trusting labels nobody has checked. Health Canada warns that unauthorized peptide drugs may contain too much, too little or none of the active ingredient, and may carry contaminants such as endotoxins. A certificate of analysis isn't a guarantee either: Paradigm Peptides admitted forging laboratory certificates, and prosecutors said all six of its SARM products that the government tested contained testosterone. The TGA has also received adverse event reports linked to unapproved peptide products, including severe allergic reactions that needed hospital care.

Doses aren't covered here. What trials and users report about amounts and schedules is in reported dosing for BPC-157 and TB-500.

What This Means in Practice

For Competitive Athletes

Under WADA's 2026 List, both peptides are prohibited at all times, and the 2027 List keeps them there. Labs have validated detection methods for both, and the strict-liability rule makes the athlete responsible for whatever a test finds.

For Everyone Else

As of October 2026, the North American and Australian regulators covered above treat research-use-only peptides sold for human use as unapproved drugs, and Health Canada and the TGA name BPC-157 and TB-500 specifically. Lawful US compounding depends on an FDA rule that hasn't been proposed yet. Personal possession hasn't been the focus of the enforcement actions above. Customs seizures and unverified product quality are still risks for every buyer.

What to Watch Next

• Whether FDA publishes a proposed rule to add BPC-157 and TB-500 to the 503A bulks list after the July 2026 committee vote, or offers interim enforcement discretion.
• The 2027 WADA List taking effect on January 1, 2027, and how WADA's final text words the new S0 reference to peptides.
• Further FDA warning letters to research-use-only sellers, and whether any name BPC-157 or TB-500 directly.